soul trial oral semaglutide cardiovascular outcomes 2024 results mace Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π SOUL: Oral Semaglutide Bests Usual
Description
Life sciences companies, physicians, investors, and patients spend a lot of time trying to understand why health plans put in place access requirements for various treatments
Lots of celebrities have now admitted to being on weight loss drugs
Expert UK guidance on managing cold sensitivity during GLP-1 treatment.
Do your clients express interest in taking GLP-1s
Modern Product Positioning
